Aptorum Group Limited Announces Results of 2020 Annual General Meeting of Shareholders
December 10 2020 - 8:00AM
Business Wire
Regulatory News:
Aptorum Group Limited (Nasdaq: APM; Euronext Paris: APM) (the
“Company”, “Aptorum Group” or “Aptorum”), a biopharmaceutical
company focused on novel technologies including the targeting of
infectious diseases, today announced the results of its 2020 annual
general meeting of shareholders, which was held on December 9,
2020, in Hong Kong.
At the annual general meeting, the required number of
shareholders of the Company:
- re-elected all of the Company’s current directors, namely Mr.
Ian Huen, Mr. Darren Lui, Dr. Clark Cheng, Mr. Charles Bathurst,
Dr. Mirko Scherer, Dr. Justin Wu and Professor Douglas Arner as
directors of the Company until the Company’s next annual general
meeting of shareholders or until their respective successors are
duly appointed and qualified; and
- approved, ratified and confirmed the re-appointment of Marcum
Bernstein & Pinchuk LLP as the Company’s independent auditors
for the year ending December 31, 2020 and authorized the Board of
Directors to fix the remuneration of the auditors.
About Aptorum Group Limited
Aptorum Group Limited (Nasdaq: APM; Euronext Paris: APM) is a
pharmaceutical company dedicated to the discovery, development and
commercialization of therapeutic assets to treat diseases with
unmet medical needs, particularly infectious diseases and cancers
(including orphan oncology indications). Aptorum’s pipeline is
enriched through the establishment of drug discovery platforms that
enable the discovery of new therapeutics assets through programs
such as the systematic screening of existing approved drug
molecules and microbiome-based research platform for treatments of
metabolic diseases. In addition to the above main focus, the
Company is pursuing therapeutic and diagnostic projects in
neurology, gastroenterology, metabolic disorders, women’s health
and other disease areas. Aptorum also has projects focused on
surgical robotics and natural supplement for women undergoing
menopause and experiencing related symptoms.
For more information about Aptorum Group, please visit
www.aptorumgroup.com.
Disclaimer and Forward-Looking Statements
This press release does not constitute an offer to sell or a
solicitation of offers to buy any securities of Aptorum Group.
This press release includes statements concerning Aptorum Group
Limited and its future expectations, plans and prospects that
constitute “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. For this purpose,
any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. In
some cases, you can identify forward-looking statements by terms
such as “may,” “should,” “expects,” “plans,” “anticipates,”
“could,” “intends,” “target,” “projects,” “contemplates,”
“believes,” “estimates,” “predicts,” “potential,” or “continue,” or
the negative of these terms or other similar expressions. Aptorum
Group has based these forward-looking statements, which include
statements regarding projected timelines for application
submissions and trials, largely on its current expectations and
projections about future events and trends that it believes may
affect its business, financial condition and results of
operations.
These forward-looking statements speak only as of the date of
this press release and are subject to a number of risks,
uncertainties and assumptions including, without limitation, risks
related to its announced management and organizational changes, the
continued service and availability of key personnel, its ability to
expand its product assortments by offering additional products for
additional consumer segments, development results, the company’s
anticipated growth strategies, anticipated trends and challenges in
its business, and its expectations regarding, and the stability of,
its supply chain, and the risks more fully described in Aptorum
Group’s Form 20-F and other filings that Aptorum Group may make
with the SEC in the future, as well as the prospectus that received
the French Autorité des Marchés Financiers visa n°20-352 on 16 July
2020.
As a result, the projections included in such forward-looking
statements are subject to change and actual results may differ
materially from those described herein. Aptorum Group assumes no
obligation to update any forward-looking statements contained in
this press release as a result of new information, future events or
otherwise.
This announcement is not a prospectus within the meaning of the
Regulation (EU) n°2017/1129 of 14 June 2017 as amended by
Regulations Delegated (EU) n°2019/980 of 14 March 2019 and
n°2019/979 of 14 March 2019.
This press release is provided “as is” without any
representation or warranty of any kind.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201210005403/en/
Inquiries: Aptorum Group Limited Investor Relations
Department investor.relations@aptorumgroup.com +44 20 80929299
Redchip – Financial Communications United States Investor Relations
Dave Gentry dave@redchip.com +1 407 491 4498 Actifin – Financial
Communications Europe Investor Relations Ghislaine Gasparetto
ggasparetto@actifin.fr +33 1 56 88 11 22
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Apr 2023 to Apr 2024